Cedars Sinai Medical Center
Los Angeles, California, 90048, United States
NCT Number: NCT03260426
Prospective randomized controlled trial investigating commencement of low residue diet versus clear liquids on postoperative zero following elective colorectal surgery, with regards to patient tolerability, incidence of nausea and/or vomiting, and postoperative length of hospitalization stay.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Los Angeles, California, 90048, United States
Offering patients, a low residue diet on the first postoperative day (POD1) after colorectal surgery is safe and improves surgical outcomes and postoperative hospital stay. Early use of low solid is superior to clear liquid diet after elective colorectal surgery.
The purpose of this study is to prospectively evaluate whether providing a patient a solid diet from postoperative day zero is superior to clear liquids. The primary endpoint measured will be patient tolerability, as evidenced by absence of vomiting. The secondary endpoints measured will be duration of supplemental intravenous hydration needed, length of hospital stay and postoperative complications, and intestinal rate measured by Abstats.
Abstats™ consists of a disposable plastic device embedded with a microphone that adheres to the abdominal wall and connects to a computer measuring acoustic event rates. The monitor will be placed on the patient's abdomen 30 minutes prior to surgery in the preoperative holding area to obtain baseline intestinal rate. The monitor will be removed prior to surgery and replaced by the surgical team in the operating room and maintained until postoperative day 3. Daily intestinal rate will be calculated as mean and median acoustic events per minute. The raw data will be analyzed by an investigator blinded to the clinical data. Intestinal rates of patients offered immediate solid feeds will be compared with those offered clear feeds. In addition, patients not tolerating or consuming early solid meal will be compared with those who do to identify whether Abstat™ can be an early predictor of diet intolerance in patients undergoing colorectal surgery.
Patients will be assigned into one of two groups:
Group I - Clear liquids on postoperative day zero immediately upon return to the floor and subsequent days' advancement of enteral diet to regular diet is as per discretion of the attending physician.
Group II - Regular diet from postoperative day zero immediately upon return to floor and onwards.
Three questionnaires assessing quality of life are to be completed by the patient, during his/her hospital stay. On postoperative day one, a self-administered questionnaire is to be completed by the patient. Please see appendix A for the questionnaire details. The same questionnaire is administered on postoperative day two and again on the last day of hospitalization.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Exclusion criteria
After randomization:
Clear liquids on postoperative day zero immediately upon return to the floor and subsequent days' advancement of enteral diet to regular diet is as per discretion of the attending physician.
Regular diet from postoperative day zero immediately upon return to floor and onwards
Intestinal rate measured by Abstats™ in patients offered immediate solid versus clear liquids after colorectal surgery
Time frame: POD 2
Patient tolerability, as evidenced by development of vomiting on postoperative day two.
Time frame: POD 0
Tolerability of regular diet will be determined by the patients ability to eat more than 50% of a solid meal on post operative day zero.
Time frame: 30 days
If antiemetics were used in
Time frame: 30 days
Length of postoperative stay
Time frame: 30 days
Development of post-operative ileus
Time frame: POD 1 and POD 2 and Discharge
Instrument title: Quality of Life Assessment Visual Analogue scale.Higher scores mean a worse outcome.
Pain score evaluated POD 1 and POD 2 and Discharge by using a self reported quality of life measure at regular intervals using a visual analog scale (0-10). A higher score means worse outcome and lower score means better outcome.
Time frame: POD 1 and POD 2 and Discharge
Instrument title: Quality of Life Assessment Visual Analogue scale.Higher scores mean a worse outcome.
Nausea Score on POD 1 and POD 2 and Discharge by using a self reported quality of life measure at regular intervals using a visual analog scale (0-10). A higher score means worse outcome and lower score means better outcome.
Time frame: POD 1 and POD 2 and Discharge
Instrument title: Quality of Life Assessment Visual Analogue scale.Higher scores mean a worse outcome.
Bloating Score on POD 1 and POD 2 and Discharge by using a self reported quality of life measure at regular intervals using a visual analog scale (0-10). A higher score means worse outcome and lower score means better outcome.
Cedars-Sinai Medical Center
Other
Prospective Randomized Controlled Trial Investigating Commencement of Low Residue Diet Versus Clear Liquids on Postoperative Zero Following Elective Colorectal Surgery
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07105527
Arrhythmias, Cardiac, Behavior
Roma, Italy
View Trial DetailsNCT01890499
Nausea, Nausea/Vomiting
Los Angeles, California, United States
View Trial DetailsNCT05676294
Nausea, Pathologic Processes
New Haven, Connecticut, United States
View Trial DetailsNCT06899217
Abdominal Pain, Digestive System Diseases
Birmingham, Alabama, United States
View Trial Details